OGRD Alliance Expands Phospholipoproteomic Platform Across Asia and MENA Regions
核心洞察
OGRD Alliance (搜索) L.L.C-FZ announces expansion of its PLPC-DB (搜索) phospholipoproteomic (搜索) module and OncoVix (搜索) Program from Dubai to Asia and MENA regions, establishing Dubai as the financial and logistical center for these markets.
The proprietary PLPC Platform integrates four scientific pillars including FDA-aligned immunobiological modules and GRAS-certified nutritional technology, supported by 11 Tier-1 congress presentations and five Q1-indexed publications.
The expansion follows formalization of manufacturing and licensing agreements with strategic partners in Japan and Singapore, positioning the American-born biotechnology system as a bridge between US innovation and global life-science investment.
OGRD Alliance (搜索) L.L.C-FZ, led by Chief Scientific Officer Dr. Ramón Gutiérrez Sandoval, M.D., has announced the strategic expansion of its PLPC-DB (搜索) phospholipoproteomic (搜索) module and OncoVix (搜索) Program from Dubai toward Asia and the MENA region. The American-born biotechnology system, backed by Q1 publications, filed patents, and FDA-aligned audits, is consolidating its presence across Asia, Europe, and the Middle East.
The expansion follows participation in international biotechnology conferences and the formalization of manufacturing and licensing agreements with strategic brokers and consultancies in Japan and Singapore. Dubai now serves as the group's financial and logistical center for Asia and the Middle East operations.
The PLPC Platform Architecture
The proprietary PLPC (Phospholipoproteomic (搜索) Complex) integrates four scientific and regulatory pillars designed for comprehensive biotechnology applications:
PLPC-DB (搜索) represents a non-cellular immunobiological module validated under FDA-aligned documentation for adaptive biotechnology applications.
PLPC-NX (搜索), designated as ABIMPROSYC (搜索), functions as a GRAS-certified nutritional technology platform synchronized with circadian and metabolic regulation systems.
STIP (Structural Traceability and Immunophenotypic Platform) ensures ex vivo validation, cross-jurisdictional reproducibility, and real-world-evidence compliance across different regulatory environments.
The platform's scientific validation is supported by 11 Tier-1 congress presentations at major conferences including ASCO, ESMO, SITC, CAP-25, and BioJapan 2025. Additionally, the platform has generated five Q1-indexed papers listed in PubMed, three international patent families filed in the United States, Japan, and Australia, and two independent pre-FDA regulatory audits confirming data integrity and traceability.
OncoVix Program Documentation
The OncoVix (搜索) Program documentation network encompasses hundreds of anonymized dossiers divided into validated sub-cohorts, representing thousands of applications under controlled real-world-evidence conditions. This extensive database demonstrates that biotechnology originating in America can achieve measurable and reproducible outcomes meeting global standards of safety and transparency.
"Our goal has always been to merge ethics, evidence, and scalability," said Dr. Ramón Gutiérrez Sandoval, Founder and Chief Scientific Officer of OGRD Alliance (搜索). "From America to Dubai and now toward Asia and MENA, OncoVix (搜索) and PLPC-DB (搜索) illustrate how data-driven innovation can transcend borders and advance global biotech standards."
Strategic Positioning and Recognition
The adjudication and asset-licensing process of the PLPC Platform is supported by leading UAE legal firms and banking brokers, ensuring regulatory transparency for forthcoming strategic transactions. This infrastructure positions the organization to facilitate international biotechnology transfers and licensing agreements.
Dr. Gutiérrez, recipient of the Visionary Award 2025 as recognized by industry peers, is scheduled as a principal speaker at year-end biotechnology and investment congresses in Dubai and Abu Dhabi, highlighting the region's growing role in next-generation life-science investment.
OGRD Alliance (搜索) operates as a biotechnology organization dedicated to the research, development, and global deployment of non-cellular immunobiological platforms. Its portfolio includes PLPC-DB (搜索), PLPC-NX (搜索), STIP, AppinProCyc, and the OncoVix (搜索) Program, recognized for integrating science, ethics, and traceability within a model of responsible innovation.